According to Zacks, “BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization BCX-4208, and is collaborating with Mundipharma for the development and commercialization of Fodosine in markets across Europe, Asia, Australia and certain neighboring countries. “
BCRX has been the topic of a number of other reports. FBR & Co reaffirmed a buy rating on shares of BioCryst Pharmaceuticals in a research note on Thursday, September 8th. JMP Securities cut shares of BioCryst Pharmaceuticals from an outperform rating to a market perform rating in a research note on Thursday, August 4th. HC Wainwright reaffirmed a buy rating on shares of BioCryst Pharmaceuticals in a research note on Friday, August 5th. Piper Jaffray Cos. raised shares of BioCryst Pharmaceuticals from a neutral rating to an overweight rating and raised their price objective for the company from $5.00 to $8.00 in a research note on Friday, August 12th. Finally, Jefferies Group raised their price objective on shares of BioCryst Pharmaceuticals from $2.00 to $3.00 and gave the company a hold rating in a research note on Friday, August 5th. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and five have assigned a buy rating to the company’s stock. The company currently has a consensus rating of Hold and an average price target of $8.22.
Shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) opened at 4.37 on Tuesday. BioCryst Pharmaceuticals has a 12 month low of $1.63 and a 12 month high of $10.98. The stock’s 50 day moving average price is $4.44 and its 200-day moving average price is $3.54. The firm’s market cap is $322.07 million.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings results on Thursday, August 4th. The biotechnology company reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.04. The business earned $4.80 million during the quarter, compared to analyst estimates of $3.92 million. BioCryst Pharmaceuticals had a negative net margin of 285.24% and a negative return on equity of 187.98%. BioCryst Pharmaceuticals’s revenue for the quarter was down 81.4% compared to the same quarter last year. During the same quarter last year, the business posted $0.06 earnings per share. Equities research analysts anticipate that BioCryst Pharmaceuticals will post ($1.03) earnings per share for the current fiscal year.
In related news, major shareholder Bros. Advisors Lp Baker sold 4,046,590 shares of the business’s stock in a transaction on Tuesday, August 16th. The shares were sold at an average price of $5.00, for a total value of $20,232,950.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Yarlagadda S. Babu sold 30,000 shares of the business’s stock in a transaction on Thursday, August 25th. The shares were sold at an average price of $4.06, for a total transaction of $121,800.00. Following the completion of the sale, the vice president now directly owns 111,428 shares in the company, valued at $452,397.68. The disclosure for this sale can be found here. 5.80% of the stock is currently owned by corporate insiders.
A number of large investors have recently bought and sold shares of BCRX. Commonwealth Equity Services Inc boosted its stake in BioCryst Pharmaceuticals by 15.7% in the second quarter. Commonwealth Equity Services Inc now owns 40,255 shares of the biotechnology company’s stock valued at $114,000 after buying an additional 5,450 shares in the last quarter. HBK Investments L P boosted its stake in BioCryst Pharmaceuticals by 152.7% in the first quarter. HBK Investments L P now owns 49,773 shares of the biotechnology company’s stock valued at $141,000 after buying an additional 30,073 shares in the last quarter. Metropolitan Life Insurance Co. NY bought a new stake in BioCryst Pharmaceuticals during the second quarter valued at approximately $180,000. ProShare Advisors LLC boosted its stake in BioCryst Pharmaceuticals by 1.4% in the second quarter. ProShare Advisors LLC now owns 63,843 shares of the biotechnology company’s stock valued at $181,000 after buying an additional 876 shares in the last quarter. Finally, Quantitative Systematic Strategies LLC bought a new stake in BioCryst Pharmaceuticals during the second quarter valued at approximately $186,000. 70.34% of the stock is currently owned by institutional investors and hedge funds.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc (BioCryst) is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. The Company uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioCryst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.